Viatris Inc. (VTRS)
Market Cap | 12.05B |
Revenue (ttm) | 14.12B |
Net Income (ttm) | -3.47B |
Shares Out | 1.17B |
EPS (ttm) | -2.92 |
PE Ratio | n/a |
Forward PE | 4.39 |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 199,813 |
Open | 10.16 |
Previous Close | 10.12 |
Day's Range | 10.10 - 10.19 |
52-Week Range | 6.85 - 13.55 |
Beta | 0.90 |
Analysts | Hold |
Price Target | 10.40 (+0.63%) |
Earnings Date | Aug 7, 2025 |
About VTRS
Viatris Inc., together with its subsidiaries, operates as a healthcare company in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, rest of Asia, Africa, Latin America, and the Middle East. It operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The company offers prescription brand drugs, generic drugs, complex generic drugs, and biosimilars. It also provides drugs in various therapeutic areas covering various noncommunicable and infectious diseases, including cardiovascular, CN... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 5 analysts, the average rating for VTRS stock is "Hold." The 12-month stock price target is $10.4, which is an increase of 0.63% from the latest price.
News

Viatris Announces Approval of First Generic Iron Sucrose Injection in the U.S.
Approval is Another Milestone of Viatris' Ability to Successfully Develop Complex Generic Medicines Approval Granted with Competitive Generic Therapy Eligibility for 100mg/5mL and 200mg/10mL Strengths...

Viatris Inc. (VTRS) Q2 2025 Earnings Call Transcript
Viatris Inc. (NASDAQ:VTRS) Q2 2025 Earnings Conference Call August 7, 2025 8:30 AM ET Company Participants Corinne M. Le Goff - Chief Commercial Officer Philippe Martin - Chief R&D Officer Scott Andr...

Xanax-maker Viatris beats quarterly profit, revenue estimates; shares rise
Drugmaker Viatris beat Wall Street estimates for second-quarter profit and revenue on Thursday, helped by demand for its products in China, sending its shares up nearly 5% in early trading.

Viatris Reports Second Quarter 2025 Results and Reiterates 2025 Financial Guidance
Delivers Total Revenues Above Expectations Reflecting the Strength of our Execution and the Resilience of our Diversified Global Business Positive Results From Five Phase 3 Data Readouts This Year Rei...

Viatris Announces Quarterly Dividend
PITTSBURGH , Aug. 5, 2025 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS) today announced that on August 4, 2025, its Board of Directors declared a quarterly dividend of $0.12 per share for each issued an...

Viatris Announces Appointment of David Simmons to the Company's Board of Directors
PITTSBURGH , Aug. 5, 2025 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that David Simmons has been appointed as the newest member of Viatris' Board of Dire...

Viatris Announces Five Data Presentations on Novel Fast-Acting Meloxicam (MR-107A-02) at PAINWeek 2025 Conference
Presentations to include efficacy, safety and opioid use reduction data in two different surgery models as well as pharmacokinetics data PITTSBURGH , Aug. 1, 2025 /PRNewswire/ -- Viatris (Nasdaq: VTR...

Viatris Hits Snag In Eye Drug Study—Phase 3 Plans Under Review
As the pharmaceutical industry increasingly focuses on developing targeted treatments for niche conditions, Viatris Inc. VTRS on Friday announced topline data from a Phase 3 study evaluating the effic...

Viatris Stock Tumbles as Eyelid Inflammation Treatment Misses Target
The pharmaceutical company says its eye inflammation treatment didn't meet its target.

Viatris eye therapy fails to meet late-stage trial goal
Viatris said on Friday that its experimental ophthalmic ointment did not meet the main goal of a late-stage study in patients with an eye condition that causes inflammation.

Viatris Provides Update on Phase 3 Study of MR-139 for Blepharitis
PITTSBURGH , July 18, 2025 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that a randomized, double-masked, vehicle-controlled, Phase 3 study to evaluate the...

Viatris: A Contrarian Bet With Virtually No Downside
Viatris has aggressively deleveraged, now poised for growth with a robust pipeline and global presence in key markets like the US, India, and China. The company's balance sheet is much improved, divid...

Dogs Of The S&P 500: 14 Ideal 'Safer' July Dividend Buys
High-yield S&P 500 stocks can be risky, but 14 "safer" S&P 500 dividend dogs have strong free cash flow to support payouts and are attractive buys. Analyst forecasts suggest top ten S&P 500 dividend d...

Viatris Announces Positive Top-Line Results from Second Pivotal Phase 3 VEGA-3 Trial of MR-141 in Presbyopia
MR-141 Met Primary And All Secondary Endpoints, Demonstrating Rapid And Sustained Improvement In Near Visual Acuity Without Compromising Distance Vision Safety Profile Consistent With Previous Clinica...

Viatris to Report Second Quarter 2025 Financial Results on August 7, 2025
PITTSBURGH , June 12, 2025 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS) will report second quarter 2025 financial results on Thursday, August 7, 2025. Company executives will host a webcast at 8:30 a.m...

Viatris Inc. (VTRS) Presents at Goldman Sachs 46th Annual Global Healthcare Conference Transcript
Viatris Inc. (NASDAQ:VTRS) Goldman Sachs 46th Annual Global Healthcare Conference June 9, 2025 10:40 AM ET Company Participants Corinne M. Le Goff - Chief Commercial Officer Philippe Martin - Chief R...

Viatris Inc. (VTRS) Presents at Jefferies Global Healthcare Conference Transcript
Viatris Inc. (NASDAQ:VTRS) Jefferies Global Healthcare Conference June 5, 2025 8:10 AM ET Company Participants Corinne M. Le Goff - Chief Commercial Officer Theodora Mistras - Chief Financial Officer...

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Viatris
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Viatris To Contact Him Directly To Discuss Their Options

Viatris Announces Positive Top-Line Results from Phase 3 LYNX-2 Trial of MR-142 in Keratorefractive Patients With Visual Disturbances Under Mesopic, Low-Contrast Conditions
MR-142 Achieved Primary Endpoint of ≥15-letter (≥3-line) Gain in Mesopic Low Contrast Distance Visual Acuity in Comparison to Placebo Results Showed Patient-Reported Functional Benefit in Treating Sig...

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Viatris
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Viatris To Contact Him Directly To Discuss Their Options If you purchased or acquired...

VTRS CLASS NOTICE: Viatris Inc. Investors may have been Affected by Fraud – Contact BFA Law before June 3 Court Deadline (NASDAQ:VTRS)
NEW YORK, May 31, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Viatris Inc. (NASDAQ: VTRS) and certain of the Company...

SHAREHOLDER REMINDER: Berger Montague Reminds Viatris (NASDAQ: VTRS) Investors of the June 3, 2025 Deadline
PHILADELPHIA, May 30, 2025 (GLOBE NEWSWIRE) -- Berger Montague PC advises investors that a securities class action lawsuit has been filed against Viatris Inc. (“Viatris” or the “Company”) (NASDAQ: VTR...

DEADLINE NEXT WEEK: Berger Montague Advises Viatris (NASDAQ: VTRS) Investors to Contact the Firm Before June 3, 2025
PHILADELPHIA, May 27, 2025 (GLOBE NEWSWIRE) -- Berger Montague PC advises investors that a securities class action lawsuit has been filed against Viatris Inc. (“Viatris” or the “Company”) (NASDAQ: VTR...

VTRS FRAUD: Suffer Losses on Viatris Inc.? You may have been Affected by Fraud and are Urged to Contact BFA Law (NASDAQ:VTRS)
NEW YORK, May 25, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Viatris Inc. (NASDAQ: VTRS) and certain of the Company...